RecruitingPhase 2NCT07316010

Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma

Studying Lymphoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Dai Chihara, MD, PHD
M.D. Anderson Cancer Center
Intervention
Leukapheresis(procedure)
Enrollment
10 target
Eligibility
18 years · All sexes
Timeline
20262031

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07316010 on ClinicalTrials.gov

Other trials for Lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Lymphoma

← Back to all trials